CompletedPhase 2NCT02352896
Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome
Studying Leigh syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PTC Therapeutics
- Principal Investigator
- Bruce Cohen, MDAkron Children's Hospital
- Intervention
- EPI-743(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 1-18 years · All sexes
- Timeline
- 2014 – 2023
Study locations (4)
- Gregory Enns, Stanford University, California, United States
- Akron Children's Hospital, Akron, Ohio, United States
- Baylor College of Medicine, Houston, Texas, United States
- Seattle Children's Hospital, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02352896 on ClinicalTrials.govOther trials for Leigh syndrome
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT06843811Sirolimus for Leigh SyndromeMatthew Demczko
- RECRUITINGNCT06967831Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural CellsCharite University, Berlin, Germany
- RECRUITINGNANCT03137355The International Registry for Leigh SyndromeThe University of Texas Health Science Center, Houston
- RECRUITINGNCT01780168The NIH MINI Study: Metabolism, Infection, and Immunity in Inborn Errors of MetabolismNational Human Genome Research Institute (NHGRI)